Inactive

The Thoracic & GI Malignancies Branch (TGMB) conducts clinical trials of new therapies to treat patients with thoracic and GI cancers who have failed standard treatments. TC-510 is a novel cell therap... The Thoracic & GI Malignancies Branch (TGMB) conducts clinical trials of new therapies to treat patients with thoracic and GI cancers who have failed standard treatments. TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells and currently investigated in the interventional clinical phase I/II trial NCT05451849. In support of this ongoing clinical trial, the TGMB requires one Brand Name or Equal MSD MESO QuickPlex SQ 120MM Plate Reader to measure two distinct biomarkers: soluble mesothelin-related peptide (SMRP) and megakaryocyte potentiating factor (MPF). See Attached Statement of Need (SON). This is a Sources Sought Notice (SSN) and is for information and planning purposes only. This notice shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this SSN is to identify qualified business concerns, especially small businesses, that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract based on responses received nor otherwise pay for the preparation of any information submitted. Responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a small business set aside is possible. The requirement’s suggested North American Industry Classification System (NAICS) code is 334516 Analytical Laboratory Instrument Manufacturing with a size standard of 1000 employees.